Compare MakeMyTrip Ltd (MMYT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Zoetis Inc — how do they compare? MakeMyTrip Ltd trades at $44.73 (market cap $4.09B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 7.4× MakeMyTrip Ltd's market cap, and Zoetis Inc pays a 2.9% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold MakeMyTrip Ltd for 12 Days and Zoetis Inc for 70 Days on average.
| MMYT | ZTS | |
|---|---|---|
Market Cap | $4.09B | $30.20B |
Volume | 1,828,010 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $94.43 | $147.53 |
52-Week Low | $36.30 | $69.09 |
Typical Hold Time | 12 Days | 70 Days |
Enterprise Value | $4.75B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMYT trades at $44.73, up 3.04% today, but technical indicators signal a bearish trend with support at $42. The stock shows mixed earnings, missing Q4 2025 and Q2 2026 estimates but beating Q1 2026. Revenue grew to $978.34M in 2025, though net income margin is thin at 3.23%. Analyst consensus is strongly bullish with a $77 price target, but cash flow turned negative in 2026, and debt-to-asset ratio surged, raising financial stability concerns.
The outlook is bifurcated: strong analyst support and a high target suggest upside, but deteriorating cash flow, rising leverage, and bearish technicals pose significant risks. Investors should weigh the potential from operational resilience and a planned Indian listing against financial volatility and macroeconomic pressures on travel demand.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
